小兒科抗癲癇藥物市場按藥物類型、給藥途徑、分銷管道和地區分類

2025 年全球小兒科抗癲癇藥物市場規模估計為 14.782 億美元，預計到 2032 年將達到 25.334 億美元，2025 年至 2032 年的複合年成長率為 8.0%。

數字。 2025年小兒科抗癲癇藥物市場佔有率（按地區）

癲癇是一種常見的神經系統疾病，影響著全世界各個年齡層的人。然而，癲癇在兒童中更為常見，因為近 70% 的癲癇患者在成年之前就被診斷出來。抗癲癇藥物在控制癲癇發作和改善癲癇的兒科患者的生活品質方面發揮著重要作用。這些藥物透過控制大腦中異常神經細胞的放電和同步來預防癲癇發作。最近的趨勢包括經過廣泛研究後開發和核准新一代小兒科抗癲癇藥物，這些藥物更有效、副作用更少。這對兒童癲癇患者的藥物順從性和治療結果有正面的影響。兒童癲癇的原因包括創傷、出生併發症和遺傳性疾病。由腦膜炎等腦部感染疾病引起的癲癇稱為症狀性癲癇，而與遺傳相關的疾病稱為特發性癲癇。

市場動態

兒童癲癇盛行率的不斷上升推動了全球小兒科抗癲癇藥物市場的發展。根據世界衛生組織 (WHO) 的數據，全球約有 1% 的兒童患有癲癇。其他推動市場成長的因素包括醫療保健成本的增加、對癲癇治療的認知的提高以及新型抗癲癇藥物的推出。然而，也存在市場限制，例如市場開發成本高以及兒科藥物核准規定嚴格。此外，抗癲癇藥物對兒童神經系統的副作用也是一個問題。另一方面，疾病修正治療的研發和個人化抗癲癇藥物治療方案的開發為新興市場進入者帶來了顯著的機會。

本研究的主要特點

• 本報告對全球小兒科抗癲癇藥物市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
• 它還強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
• 全球小兒科抗癲癇藥物市場的主要公司概況是根據公司亮點、產品系列、主要亮點、業績和策略等參數進行的。
• 本研究涉及的主要企業包括賽諾菲、Eisai、輝瑞、UCB SA、Sunovion Pharmaceuticals、雅培、Jazz Pharmaceuticals、Ovid Therapeutics Inc.、SK BIOPHARMACEUTICALS、Alexza Pharmaceuticals, Inc.、Taisho Pharmaceutical Holdings、Marinus Pharmaceutical) Industries Ltd.。
• 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。
• 全球小兒科抗癲癇藥物市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
• 相關人員可以透過用於分析全球小兒科抗癲癇藥物市場的各種策略矩陣來簡化決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
• 神經系統疾病發生率增加
• 增加研發活動
  • 限制因素
• 監管機構增加產品召回
• 抗癲癇藥物的副作用
  • 市場機會
• 尚未開發的新興市場
• 標靶治療需求不斷成長
• 影響分析
• 監管指南
• 產品發布
• 主要進展
• PEST分析
• 波特分析
• 監管情景
• 合併與收購
• 製造商收益
• 各國醫療保健支出

第4章全球小兒科抗癲癇藥物市場-COVID-19影響分析

• 整體影響
• 政府舉措
• COVID-19 市場影響

第5章 2020 年至 2032 年小兒科抗癲癇藥物市場（依藥物類型）

• 第一代抗癲癇藥物
• 第二代抗癲癇藥物
• 第三代抗癲癇藥物

第6章小兒科抗癲癇藥物市場（依給藥途徑），2020 年至 2032 年

• 口服
• 注射
• 其他（鼻腔等）

第7章小兒科抗癲癇藥物市場（依分銷管道分類），2020 年至 2032 年

• 醫院藥房
• 零售藥局
• 網路藥局

第 8 章小兒科抗癲癇藥物市場（按地區分類），2020-2032 年

• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章 競爭態勢

• Sanofi
• Eisai Co., Ltd.
• Pfizer Inc.
  • Company Highlight
• UCB SA
• Sunovion Pharmaceuticals Inc.
• Abbott
• Jazz Pharmaceuticals plc
• Ovid Therapeutics Inc.
• SK BIOPHARMACEUTICALS
• Alexza Pharmaceuticals, Inc.
• Taisho Pharmaceutical Holdings Co., Ltd.
• Marinus Pharmaceuticals, Inc.
• Xenon Pharmaceuticals Inc.
• Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.

第 10 章 章節

• 調查方法
• 關於出版商

Global Anti-Epileptic Drugs for Pediatrics Market is estimated to be valued at USD 1,478.2 Mn in 2025 and is expected to reach USD 2,533.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2032.

Figure. Anti-Epileptic Drugs For Pediatrics Market Share (%), By Region 2025

Epilepsy is a common neurological disorder that affects people of all ages globally. However, it is more prevalent in children as almost 70% of epilepsy cases are diagnosed before reaching adulthood. Anti-epileptic drugs play a crucial role in managing seizures and improving quality of life for pediatric patients suffering from epilepsy. These medications work by controlling abnormal neuronal firing and synchrony in the brain to prevent seizures. In recent years, extensive research has led to the development and approval of newer generation anti-epileptic drugs that are more effective and have less side effects than the earlier drugs for pediatric use. This has positively impacted medication adherence and treatment outcomes for children with epilepsy. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while a genetics related condition is called idiopathic epilepsy.

Market Dynamics

The global anti-epileptic drugs for pediatrics market is driven by the growing prevalence of epilepsy among children. According to the World Health Organization (WHO), epilepsy affects around 1% of children worldwide. Besides this, factors such as increasing healthcare expenditures, rising awareness about epilepsy treatment, and introduction of newer anti-epileptic drugs are fueling the market growth. However, the market faces certain restraints such as high costs associated with drug development and stringent regulations for the approval of pediatric drugs. Moreover, adverse effects of anti-epileptic drugs on developing neurological system of children poses challenges. On the positive side, ongoing research on disease modifying therapies and development of personalized anti-epileptic drug regimens present notable opportunities for market players in the future.

Key features of the study:

• This report provides an in-depth analysis of the global anti-epileptic drugs for pediatrics market, and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anti-epileptic drugs for pediatrics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as part of this study include Sanofi, Eisai Co., Ltd., Pfizer Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Abbott, Jazz Pharmaceuticals plc, Ovid Therapeutics Inc., SK BIOPHARMACEUTICALS, Alexza Pharmaceuticals, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Marinus Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., H. Lundbeck A/S, and Teva Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics
• The global anti-epileptic drugs for pediatrics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs for pediatrics market

Detailed Segmentation:

• Global Anti-Epileptic Drugs for Pediatrics Market, Drug Type:
  • First generation anti-epileptic drugs
  • Second generation anti-epileptic drugs
  • Third generation anti-epileptic drugs
• Global Anti-Epileptic Drugs for Pediatrics Market, Route of Administration:
  • Oral
  • Injectable
  • Others (Nasal, etc.)
• Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Anti-Epileptic Drugs for Pediatrics Market, By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles
  • Sanofi
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • UCB S.A.
  • Sunovion Pharmaceuticals Inc.
  • Abbott
  • Jazz Pharmaceuticals plc
  • Ovid Therapeutics Inc.
  • SK BIOPHARMACEUTICALS
  • Alexza Pharmaceuticals, Inc.
  • Taisho Pharmaceutical Holdings Co., Ltd.
  • Xenon Pharmaceuticals Inc.
  • Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trend Analysis

• Market Dynamics
  • Drivers
• Increasing incidence of neurological disorders
• Increasing research and development activities
  • Restraints
• Increasing product recalls by regulatory authorities
• Side effects of anti-epileptic drugs
  • Market Opportunities
• Untapped emerging markets
• The rising demand for targeted therapy
• Impact Analysis
• Regulatory Guidelines
• Product Launches
• Key Development
• PEST Analysis
• PORTER's Analysis
• Regulatory Scenario
• Mergers and Acquisitions
• Manufacturer Revenue
• Healthcare Spending by Country

4. Global Anti-Epileptic Drugs for Pediatrics Market - COVID-19 Impact Analysis

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, 2020-2032, (US$ Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• First generation anti-epileptic drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Second generation anti-epileptic drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Third generation anti-epileptic drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global Anti-Epileptic Drugs for Pediatrics Market, By Route of Administration, 2020-2032, (US$ Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Others (Nasal, etc.)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global Anti-Epileptic Drugs for Pediatrics Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020- 2032, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020- 2032, (US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Eisai Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlight
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• UCB S.A.
• Sunovion Pharmaceuticals Inc.
• Abbott
• Jazz Pharmaceuticals plc
• Ovid Therapeutics Inc.
• SK BIOPHARMACEUTICALS
• Alexza Pharmaceuticals, Inc.
• Taisho Pharmaceutical Holdings Co., Ltd.
• Marinus Pharmaceuticals, Inc.
• Xenon Pharmaceuticals Inc.
• Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.

10. Section

• Research Methodology
• About Us